X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Takeda selected for the sixth consecutive year for Dow Jones Sustainability Asia Pacific Index

Yuvraj_pawp by Yuvraj_pawp
5th October 2015
in Facilities & Operation

Takeda Pharmaceutical Company Ltd. (“Takeda”, TSE: 4502) has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific) for the sixth consecutive year. Takeda has been included in the DJSI Asia Pacific since 2010 for its sustainability performance.

DJSI Asia Pacific is part of the Dow Jones Sustainability Indexes (DJSI). It is designed for companies in the developed Asia Pacific markets and comprises 145 companies, including 62 Japanese companies, that are leading the way in terms of sustainability among the 600 companies in the region. For inclusion in the DJSI Asia Pacific, Dow Jones assesses companies based on questionnaire responses, annual reports from each company and publicly available company information.

For Takeda, CSR is rooted in putting the patient in the center and operating a pharmaceutical business that creates outstanding products. The company also strives to maintain and improve sound business processes, and to engage in activities to promote a sustainable society as a good corporate citizen. In doing so, it is implementing a model of value creation and preservation through CSR. This will help Takeda to build trust with society, reinforce its reputation, and further develop the pharmaceutical business.

Takeda promotes CSR activities in line with internationally recognized guidelines, such as the United Nations Global Compact’s 10 principles. The company is also included in the FTSE4Good Global Index by the FTSE Group and the Morningstar Socially Responsible Investment Index (MS-SRI) compiled by Morningstar Japan K.K.

DJSI is one of the world’s foremost indices for Socially Responsible Investment. It assesses and selects leading sustainability-driven companies based on economic, environmental, and social criteria. Thus it serves as an important indicator for investors considering corporate social responsibility (CSR) performance. It is provided by S&P Dow Jones Indices LLC of the United States.

Previous Post

Gencia and Takeda Team to Discover and Develop Novel Class of Mitochondrial Therapeutics

Next Post

Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan

Related Posts

India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
CPhI Pharma Index Shows Unprecedented Global Pharma Optimism
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
CPHI Report Says, Biologics Outsourcing Will Surge In 2023
Facilities & Operation

CPHI Report Says, Biologics Outsourcing Will Surge In 2023

28th October 2022
Facilities & Operation

Gates Foundation Commits $1.2 Billion To Root Out Polio

20th October 2022
Facilities & Operation

RNA Vaccine UK Innovation Centre At CPI Gets Fresh Funding

11th October 2022
Facilities & Operation

To Aid Keytruda And Gardasil, Merck Expands Singapore Hub

8th October 2022
Next Post

Takeda Submits a New Drug Application for the Fixed-Dose Combination of Nesina® and Metformin Hydrochloride for the Treatment of Type 2 Diabetes in Japan

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In